These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26880862)

  • 1. Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-κB Pathway in Type 2 Diabetic db/db Mice.
    Chen XW; Du XY; Wang YX; Wang JC; Liu WT; Chen WJ; Li HY; Peng FF; Xu ZZ; Niu HX; Long HB
    Mediators Inflamm; 2016; 2016():1405924. PubMed ID: 26880862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclopropanyldehydrocostunolide LJ attenuates high glucose-induced podocyte injury by suppressing RANKL/RANK-mediated NF-κB and MAPK signaling pathways.
    Chen XW; Liu WT; Wang YX; Chen WJ; Li HY; Chen YH; Du XY; Peng FF; Zhou WD; Xu ZZ; Long HB
    J Diabetes Complications; 2016 Jul; 30(5):760-9. PubMed ID: 27052152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of GSK-3β inhibitor on the expression of RANK-RANKL in rats kidney tissue with diabetic nephropathy].
    Zhou YX; Guo YH; Li L; Lyu LS; Qin Y; Li XJ; Xu K; Yu YN
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):945-950. PubMed ID: 30522177
    [No Abstract]   [Full Text] [Related]  

  • 4. Irbesartan ameliorates hyperlipidemia and liver steatosis in type 2 diabetic db/db mice via stimulating PPAR-γ, AMPK/Akt/mTOR signaling and autophagy.
    Zhong J; Gong W; Lu L; Chen J; Lu Z; Li H; Liu W; Liu Y; Wang M; Hu R; Long H; Wei L
    Int Immunopharmacol; 2017 Jan; 42():176-184. PubMed ID: 27919004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-Shogaol ameliorates diabetic nephropathy through anti-inflammatory, hyperlipidemic, anti-oxidative activity in db/db mice.
    Xu Y; Bai L; Chen X; Li Y; Qin Y; Meng X; Zhang Q
    Biomed Pharmacother; 2018 Jan; 97():633-641. PubMed ID: 29101807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor activator of NF-kappaB and podocytes: towards a function of a novel receptor-ligand pair in the survival response of podocyte injury.
    Liu S; Shi W; Xiao H; Liang X; Deng C; Ye Z; Mei P; Wang S; Liu X; Shan Z; Liang Y; Zhang B; Wang W; Liu Y; Xu L; Xia Y; Ma J; Li Z
    PLoS One; 2012; 7(7):e41331. PubMed ID: 22848465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
    Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC
    Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-451 suppresses the NF-kappaB-mediated proinflammatory molecules expression through inhibiting LMP7 in diabetic nephropathy.
    Sun Y; Peng R; Peng H; Liu H; Wen L; Wu T; Yi H; Li A; Zhang Z
    Mol Cell Endocrinol; 2016 Sep; 433():75-86. PubMed ID: 27264074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.
    Sen S; Kanter M; Ustundag S; Aktas C; Dogutan H; Yalcin O
    Ren Fail; 2008; 30(10):1023-33. PubMed ID: 19016156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation.
    Ock S; Ahn J; Lee SH; Park H; Son JW; Oh JG; Yang DK; Lee WS; Kim HS; Rho J; Oh GT; Abel ED; Park WJ; Min JK; Kim J
    Cardiovasc Res; 2012 Apr; 94(1):105-14. PubMed ID: 22298642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An aqueous extract of Portulaca oleracea ameliorates diabetic nephropathy through suppression of renal fibrosis and inflammation in diabetic db/db mice.
    Lee AS; Lee YJ; Lee SM; Yoon JJ; Kim JS; Kang DG; Lee HS
    Am J Chin Med; 2012; 40(3):495-510. PubMed ID: 22745066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Irbesartan ameliorates cardiac inflammation in type 2 diabetic db/db mice].
    Ye XL; Huang WC; Zheng YT; Liang Y; Gong WQ; Yang CM; Liu B
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 37(4):505-511. PubMed ID: 28446404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prospective treatment study of irbesartan. Diabetic kidneys regain function].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145(41):41. PubMed ID: 14655481
    [No Abstract]   [Full Text] [Related]  

  • 15. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
    Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANKL/RANK contributes to the pathological process of type 2 diabetes mellitus through TRAF3 activation of NIK.
    Yu J; Tian N; Hu Y; Jin T
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113008. PubMed ID: 39217877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury.
    Liu W; Zhang X; Liu P; Shen X; Lan T; Li W; Jiang Q; Xie X; Huang H
    Eur J Pharmacol; 2010 Jul; 638(1-3):150-5. PubMed ID: 20447389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of active components of Xiexin decoction ameliorates renal fibrosis through the inhibition of NF-κB and TGF-β1/Smad pathways in db/db diabetic mice.
    Wu JS; Shi R; Lu X; Ma YM; Cheng NN
    PLoS One; 2015; 10(3):e0122661. PubMed ID: 25803610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timosaponin B-II ameliorates diabetic nephropathy via TXNIP, mTOR, and NF-κB signaling pathways in alloxan-induced mice.
    Yuan YL; Guo CR; Cui LL; Ruan SX; Zhang CF; Ji D; Yang ZL; Li F
    Drug Des Devel Ther; 2015; 9():6247-58. PubMed ID: 26664046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.